Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 210 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Athyros, Vasilios G [Clear All Filters]
Mortality reduction in patients treated with intensive lipid therapy vs usual care. Re: Zhao XQ, Phan BA, Davis J et al. Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Tre.
J Clin Lipidol. 11(1), 306-307.
(2017). Semaglutide, lipid-lowering drugs, and NAFLD..
Lancet Diabetes Endocrinol. 5(5), 329-330.
(2017).
(2017). Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?.
J Clin Hypertens (Greenwich). 18(10), 1073.
(2016). Current challenges in antihypertensive treatment in the elderly..
Pol Arch Med Wewn. 126(7-8), 540-51.
(2016). Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?.
Curr Vasc Pharmacol. 14(6), 494-497.
(2016). Editorial: Cardiovascular Disease Mortality Rates are Plateauing in Certain Age Groups and Regions. Can we Keep them Declining?.
Curr Vasc Pharmacol. 14(3), 271-4.
(2016). Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs..
Curr Vasc Pharmacol. 14(2), 208-10.
(2016). Exploring the Management of Statin Intolerant Patients: 2016 and Beyond..
Curr Vasc Pharmacol. 14(6), 523-533.
(2016). High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes. Implications for everyday practice..
J Diabetes Complications. 30(1), 9-11.
(2016). Off target effects of statins shape total mortality?.
J Drug Assess. 5(1), 4-5.
(2016). Statins and non-alcoholic steatohepatitis..
J Hepatol. 64(1), 241-2.
(2016). Statins and Type 2 Diabetes Mellitus: An Update After 1 Year..
Curr Pharm Des. 22(18), 2723-5.
(2016). Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?.
Curr Vasc Pharmacol. 14(1), 88-97.
(2016).
(2016). Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update..
World J Gastroenterol. 21(22), 6820-34.
(2015). Cardiovascular Risk in Middle East Populations: A Call to Action..
Angiology. 66(9), 801-2.
(2015). Contrast-Induced Nephropathy: An "All or None" Phenomenon?.
Angiology. 66(6), 508-13.
(2015). Editorial: effect of statins on rates of long-term cardiovascular events and restenosis following carotid endarterectomy..
Curr Vasc Pharmacol. 13(2), 223-5.
(2015). Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease..
Curr Vasc Pharmacol. 13(3), 366-7.
(2015). Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not AII..
Curr Vasc Pharmacol. 13(6), 696-8.
(2015). The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials..
Eur Heart J. 36(24), 1536-46.
(2015). Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment..
Curr Vasc Pharmacol. 13(6), 788-800.
(2015). Genetic, epidemiologic and clinical data strongly suggest that fasting or non-fasting triglycerides are independent cardiovascular risk factors..
Curr Med Res Opin. 31(3), 435-8.
(2015). High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus..
J Diabetes Complications. 29(1), 142-5.
(2015).